Debra Patt

2 weeks ago | oncologynewscentral.com | Debra Patt |Robert A. Figlin

This transcript has been lightly edited for clarity. Robert A. Figlin, MD, FACP: Good afternoon. This is Bob Figlin, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles. And I’m absolutely delighted today to be joined by Debra Patt, who is both a practicing oncologist and breast cancer specialist in Austin, Texas.

2 months ago | ajmc.com | Mary Caffrey |Debra Patt

Debra Patt, MD, PhD, MBA, MPH, serves as executive vice president of Texas Oncology, medical director for public policy for The US Oncology Network, and most recently, president of the Community Oncology Alliance. In this interview, Patt highlights how artificial intelligence (AI) is poised to revolutionize oncology care, from diagnostics to clinical decision support.

2 months ago | ajmc.com | Mary Caffrey |Debra Patt

Debra Patt, MD, PhD, MBA, MPH, executive vice president of Texas Oncology, medical director for public policy for The US Oncology Network, and new president of the Community Oncology Alliance, highlights the growing burden of prior authorization on oncology practices, describing it as an "inappropriate barrier" that delays patient care and increases administrative costs.

2 months ago | ajmc.com | Mary Caffrey |Debra Patt

Debra Patt, MD, PhD, MBA, MPH, serves as executive vice president of Texas Oncology, medical director for public policy for The US Oncology Network, and now, president of the Community Oncology Alliance (COA). In an interview from January 10, 2025, she emphasized the urgent need for policy reforms to improve patient access to care, highlighting key issues such as pharmacy benefit manager (PBM) transparency, potential changes to 340B reimbursement, and physician reimbursement challenges.

Apr 9, 2024 | obroncology.com | Debra Patt

When it comes to changing policies detrimental to community oncology, doctors can make a difference "simply by showing up," says Debra Patt, MD, PhD, MBA, a medical oncologist and executive vice president at Texas Oncology. She describes how her recent testimony on Capitol Hill went and explains why it’s so important for oncologists to interact with elected representatives at both the state and federal level.